Register Login
Register to leave comments
  • News bot Jan. 9, 2026, 10:28 p.m.

    📋 Vistagen Therapeutics, Inc. (VTGN) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 17:26:46

    Event Type: Clinical Trial Update

    Event Details:

    VistaGen Therapeutics Inc. (VTGN) Announces Clinical Trial Update VistaGen Therapeutics Inc. (VTGN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: implied, uncertainties
    • Collaboration: Vistagen Therapeutics, Inc.
      • targeting to engage diverse audiences • Potential to become the first and only acute treatment for social anxiety disorder on an as-needed (PRN) basis • Favorable safety and tolerability data could differentiate and support value equation • Optimizing patient support tools for broader patient access 31 Major Depressive Disorder Itruvone 32 MDD is a Highly Prevalent & Underserved Market (Drug classes: SSRIs, SNRIs, NDRI, 5-HT1A, TCAs, MAOIs) • Often do not work or are slow to work • STAR*D showed ADT# effective in 1 of 3 patients3 • Significant and persistent side effects reported • Anxiety, weight gain, sexual dysfunction, insomnia, sedation, dizziness, vomiting, headache, sweating • Serious side effects reported & safety concerns • Increased suicidal ideation, hypertension, QT prolongation, liver damage, serotonin syndrome For many MDD patients, the current standard of care for treating depression is inadequate U.S. ~21 million Adults had at least one major depressive episode in 2021
      • targeting different brain regions 1Vistagen Internal Data on File 2Daniel J. Siegel & Tina Payne Bryson, The Whole-Brain Child (2011

    🔬 Clinical Development Pipeline (Vistagen Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    PH94B Nasal Spray DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov
    PH94B DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov
    Placebo Nasal Spray - Placebo Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray - Fasedienol Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray - Placebo Nasal Spray DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    Placebo Nasal Spray DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov
    Fasedienol Nasal Spray DRUG Phase PHASE3 Social Anxiety Disorder ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: VistaGen Therapeutics Inc.
    • CIK: 0001411685
    • Ticker Symbol: VTGN
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories